Advertisement
Advertisement
U.S. Markets open in 3 hrs 26 mins
Advertisement
Advertisement
Advertisement
Advertisement

Synthetic Biologics, Inc. (SYN)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
0.2290+0.0290 (+14.50%)
At close: 04:00PM EDT
0.2200 -0.01 (-3.93%)
Pre-Market: 05:09AM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.2000
Open0.2100
Bid0.2150 x 800
Ask0.2200 x 800
Day's Range0.2092 - 0.2315
52 Week Range0.2000 - 0.7200
Volume1,238,722
Avg. Volume2,948,698
Market Cap30.238M
Beta (5Y Monthly)1.68
PE Ratio (TTM)N/A
EPS (TTM)-0.2240
Earnings DateMar 02, 2022 - Mar 07, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Benzinga

    Synthetic Biologics Posts Encouraging Safety Data on SYN-020 In Healthy Volunteers

    Synthetic Biologics Inc (NYSE: SYN) has announced safety data from its Phase 1 multiple ascending dose (MAD) trial of SYN-020 intestinal alkaline phosphatase (IAP). The Phase 1 MAD study enrolled 32 healthy adult volunteers into four cohorts with SYN-020 administered orally in doses ranging from 5 mg to 75 mg twice daily for 14 days, with a follow-up evaluation at day 35. SYN-020 is a recombinant bovine IAP formulated for oral delivery to the small intestine and designed to diminish fat absorpti

  • GlobeNewswire

    Synthetic Biologics Reports Positive Safety Data on SYN-020 Intestinal Alkaline Phosphatase Phase 1 Multiple Ascending Dose Clinical Trial

    -Orally administered SYN-020 observed to be well tolerated across all doses in healthy volunteers- ROCKVILLE, Md., May 10, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced positive safety data from its Phase 1, placebo-controlled, double-blind multiple ascending dose (MAD) clinical trial of SYN-020 intestinal alkaline phosphatase (IAP). The

  • GlobeNewswire

    Synthetic Biologics to Host Conference Call and Webcast to Discuss First Quarter 2022 Operational Highlights and Financial Results

    ROCKVILLE, Md., May 09, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced that it plans to host a conference call on Monday, May 16, 2022, at 8:30 a.m. ET to discuss its financial results for the quarter ended March 31, 2022 and provide a corporate update. Individuals may participate in the live call via telephone by dialing (877) 451-6152 (d

Advertisement
Advertisement